| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |